Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
For brand manufacturers managing lifecycle transitions, the analytical priority is identifying which drugs in the portfolio are Cost Plus-vulnerable meaning they have generic or biosimilar competitors with APIs available at manufacturing cost that Cost Plus could list at prices far below current protected pricing and which drugs have genuine clinical differentiation that would withstand direct cost-plus price competition
Tanycyte, the neuron whisperer
This is an exciting avenue for future research
It has also given plenty of scientific support for conditions such as nonalcoholic fatty liver disease, cardiovascular health problems and a host of different applications to neurodegenerative diseases from Alzheimer's Disease to Parkinson's
US$ 29.03
US$ 21.31
US$ 27.32
US$ 23.51
